Linked Life Data

20538094

Source:http://linkedlifedata.com/resource/pubmed/id/20538094

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
32
pubmed:dateCreated
2010-7-21
pubmed:abstractText
This study assessed the immunogenicity and safety of a human rotavirus vaccine RIX4414; the effect of co-administration of childhood vaccines on the immune responses was also assessed. Healthy infants aged 6-14 weeks received two doses of RIX4414/placebo concomitantly with the primary childhood vaccination (Infanrix hexa, Infanrix quinta,Meningitec and/or Prevnar), respecting the vaccination schedule of each country. Anti-rotavirus IgA seroconversion rate (ELISA cut-off 20 U/ml) was measured pre-vaccination and 1-2 months post-Dose 2. Immune response against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b, inactivated polio virus, pneumococcal polysaccharide conjugate (France and Germany) and meningococcal group C conjugate vaccines (Spain) were measured approximately 1-month post-Dose 3. An overall anti-rotavirus IgA seroconversion rate of 86.5%(95% CI: 83.9-88.8) was observed in the RIX4414 group 1-month post-Dose 2. The seroconversion rate in Finland and Italy (3 and 5-month schedule) was 94.6%(95% CI: 90.0-97.5) and 92.3%(95% CI: 64.0-99.8), respectively. Immune response to the childhood vaccines was unaffected following co-administration with RIX4414. Reactogenicity profile was similar for RIX4414 and placebo groups. RIX4414 was immunogenic and well tolerated in European infants and the co-administration of routine childhood vaccines with RIX4414 did not negatively impact the immune responses to these vaccines.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Viral, http://linkedlifedata.com/resource/pubmed/chemical/Diphtheria-Tetanus-acellular..., http://linkedlifedata.com/resource/pubmed/chemical/Haemophilus Vaccines, http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B Vaccines, http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin A, http://linkedlifedata.com/resource/pubmed/chemical/Pneumococcal Vaccines, http://linkedlifedata.com/resource/pubmed/chemical/Poliovirus Vaccine, Inactivated, http://linkedlifedata.com/resource/pubmed/chemical/RIX4414 vaccine, http://linkedlifedata.com/resource/pubmed/chemical/Rotavirus Vaccines, http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Attenuated, http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Combined, http://linkedlifedata.com/resource/pubmed/chemical/heptavalent pneumococcal conjugate..., http://linkedlifedata.com/resource/pubmed/chemical/infanrix hexa
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1873-2518
pubmed:author
pubmed:copyrightInfo
(c) 2010 Elsevier Ltd. All rights reserved.
pubmed:issnType
Electronic
pubmed:day
19
pubmed:volume
28
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
5272-9
pubmed:dateRevised
2010-10-6
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe.
pubmed:affiliation
University of Tampere, Medical School, FIN-33014 Tampere, Finland. timo.vesikari@uta.fi
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III